Inpellis

Inpellis was a U.S. specialty pharmaceutical company focused on developing and commercializing transdermal prescription therapeutics for pain associated with musculoskeletal disorders and peripheral neuropathy. The company centered its approach on the endel transdermal drug delivery system, a platform intended to enable non-invasive delivery of FDA-approved drugs through the skin for non-dermal pain indications. Inpellis was founded in 2012, was formerly known as Alterix, and was headquartered in Haddonfield, New Jersey. The company pursued an IPO under the ticker INPL, but the offering was cancelled, and the business is now out of operation. Publicly available sources indicate the company had a small team and did not reach commercialization.